Generic Giapreza Availability
Last updated on Apr 10, 2025.
Giapreza is a brand name of angiotensin II, approved by the FDA in the following formulation(s):
GIAPREZA (angiotensin ii acetate - solution;intravenous)
-
Manufacturer: LA JOLLA PHARMA
Approval date: December 21, 2017
Strength(s): EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML) [RLD], EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML) (discontinued) [RLD] -
Manufacturer: LA JOLLA PHARMA
Approval date: December 23, 2021
Strength(s): EQ 0.5MG BASE/ML (EQ 0.5MG BASE/ML) [RLD]
Is there a generic version of Giapreza available?
No. There is currently no therapeutically equivalent version of Giapreza available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Giapreza. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Angiotensin II alone or in combination for the treatment of hypotension
Patent 10,028,995
Issued: July 24, 2018
Inventor(s): Chawla Lakhmir
Assignee(s): The George Washington University a Congressionally Chartered Not-for-Profit CorporationThe present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 65 mm or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm to the equivalent of about 0.05-0.2 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less.
Patent expiration dates:
- December 18, 2034✓
- December 18, 2034
-
Method of treating low blood pressure
Patent 10,335,451
Issued: July 2, 2019
Inventor(s): Chawla Lakhmir
Assignee(s): The George Washington University a Congressionally Chartered Not-for-Profit CorporationA method for treating a patient suffering from one of septic shock, acute kidney injury, severe hypotension, cardiac arrest, and refractory hypotension, but not from myocardial infarction, is provided. The method includes administering a therapeutically effective dose of Angiotensin II, or Ang II, to the patient.
Patent expiration dates:
- December 16, 2029✓
- December 16, 2029
-
Angiotensin II alone or in combination for the treatment of hypotension
Patent 10,493,124
Issued: December 3, 2019
Inventor(s): Chawla Lakhmir S.
Assignee(s): The George Washington University a Congressionally Chartered Not-for-Profit CorporationThe present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 65 mm Hg or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm Hg to the equivalent of about 0.05-0.2 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less.
Patent expiration dates:
- December 18, 2034✓
- December 18, 2034
-
Method of treating low blood pressure
Patent 10,500,247
Issued: December 10, 2019
Inventor(s): Chawla Lakhmir
Assignee(s): The George Washington University a Congressionally Chartered Not-for-Profit CorporationA method for treating a patient suffering from one of septic shock, acute kidney injury, severe hypotension, cardiac arrest, and refractory hypotension, but not from myocardial infarction, is provided. The method includes administering a therapeutically effective dose of Angiotensin II, or Ang II, to the patient.
Patent expiration dates:
- December 16, 2029✓
- December 16, 2029✓
- December 16, 2029
-
Method of treating low blood pressure
Patent 10,548,943
Issued: February 4, 2020
Inventor(s): Chawla Lakhmir S.
Assignee(s): The George Washington University a Congressionally Chartered Not-for-Profit CorporationA method for treating a patient suffering from one of septic shock, acute kidney injury, severe hypotension, cardiac arrest, and refractory hypotension, but not from myocardial infarction, is provided. The method includes administering a therapeutically effective dose of Angiotensin II, or Ang II, to the patient.
Patent expiration dates:
- December 16, 2029✓
- December 16, 2029✓
- December 16, 2029
-
Angiotensin II alone or in combination for the treatment of hypotension
Patent 11,096,983
Issued: August 24, 2021
Inventor(s): Chawla Lakhmir S.
Assignee(s): The George Washington University a Congressionally Chartered Not-for-Profit CorporationThe present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 6.5 mm Hg or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm Hg to the equivalent of about 0.05-0.2 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less.
Patent expiration dates:
- December 18, 2034✓
- December 18, 2034✓
- December 18, 2034
-
Methods for treating hypotension in a patient that has received an ACE inhibitor by administering angiotensin II
Patent 11,219,662
Issued: January 11, 2022
Inventor(s): Tidmarsh George & Chawla Lakhmir
Assignee(s): La Jolla Pharma, LLCThe present disclosure relates to the use of angiotensin II, angiotensin III, or angiotensin IV in therapeutic methods for the treatment of hypotension, especially catecholamine-resistant hypotension.
Patent expiration dates:
- January 6, 2037✓
- January 6, 2037
-
Angiotensin II alone or in combination for the treatment of hypotension
Patent 11,559,559
Issued: January 24, 2023
Inventor(s): Chawla; Lakhmir S.
Assignee(s): The George Washington University, A Congressionally Chartered Not-For-Profit Corporation (Washington, DC)The present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 65 mm Hg or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm Hg to the equivalent of about 0.05-0.2 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less.
Patent expiration dates:
- December 18, 2034✓
- December 18, 2034
-
Angiotensin II alone or in combination for the treatment of hypotension
Patent 9,220,745
Issued: December 29, 2015
Inventor(s): Chawla Lakhmir
Assignee(s): The George Washington University, a Congressionally Not-for-Profit CorporationThe present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 65 mm Hg or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm Hg to the equivalent of about 0.05-0.2 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less.
Patent expiration dates:
- December 18, 2034✓
- December 18, 2034✓
- December 18, 2034
-
Method of treating low blood pressure
Patent 9,572,856
Issued: February 21, 2017
Inventor(s): Chawla Lakhmir
Assignee(s): The George Washington University a Congressionally Chartered Not-for-Profit CorporationA method for treating a patient suffering from one of septic shock, acute kidney injury, severe hypotension, cardiac arrest, and refractory hypotension, but not from myocardial infarction, is provided. The method includes administering a therapeutically effective dose of Angiotensin II, or Ang II, to the patient.
Patent expiration dates:
- July 18, 2031✓
- November 20, 2030✓
- July 18, 2031
-
Method of treating low blood pressure
Patent 9,867,863
Issued: January 16, 2018
Inventor(s): Chawla Lakhmir
Assignee(s): The George Washington University a Congressionally Chartered Not-for-Profit CorporationA method for treating a patient suffering from one of septic shock, acute kidney injury, severe hypotension, cardiac arrest, and refractory hypotension, but not from myocardial infarction, is provided. The method includes administering a therapeutically effective dose of Angiotensin II, or Ang II, to the patient.
Patent expiration dates:
- December 16, 2029✓
- December 16, 2029
More about Giapreza (angiotensin II)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: vasopressors
Patient resources
Professional resources
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.